Technical Analysis for FWBI - First Wave BioPharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -4.71% | |
| Bollinger Band Squeeze | Range Contraction | -4.71% | |
| Outside Day | Range Expansion | -4.71% | |
| 20 DMA Support | Bullish | -5.35% | |
| Bollinger Band Squeeze | Range Contraction | -5.35% | |
| BB Squeeze Started | Range Contraction | -5.35% | |
| Up 3 Days in a Row | Strength | -5.35% | |
| Up 4 Days in a Row | Strength | -5.35% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 10 hours ago |
| Up 2% | about 11 hours ago |
| Up 1% | about 11 hours ago |
| 20 DMA Support | about 12 hours ago |
| 10 DMA Support | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/21/2024
First Wave BioPharma, Inc. Description
First Wave BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. First Wave BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Health Sciences Pharmacy Therapeutic Products Diarrhea Checkpoint Inhibitor Gastrointestinal Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.998 |
| 52 Week Low | 2.3335 |
| Average Volume | 73,362 |
| 200-Day Moving Average | 5.56 |
| 50-Day Moving Average | 3.85 |
| 20-Day Moving Average | 2.80 |
| 10-Day Moving Average | 2.79 |
| Average True Range | 0.32 |
| RSI (14) | 41.52 |
| ADX | 23.94 |
| +DI | 17.05 |
| -DI | 22.57 |
| Chandelier Exit (Long, 3 ATRs) | 2.45 |
| Chandelier Exit (Short, 3 ATRs) | 3.29 |
| Upper Bollinger Bands | 3.09 |
| Lower Bollinger Band | 2.51 |
| Percent B (%b) | 0.55 |
| BandWidth | 20.94 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.34 |
| MACD Histogram | 0.101 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.28 | ||||
| Resistance 3 (R3) | 3.30 | 3.17 | 3.21 | ||
| Resistance 2 (R2) | 3.17 | 3.06 | 3.16 | 3.18 | |
| Resistance 1 (R1) | 3.00 | 2.98 | 2.94 | 2.98 | 3.15 |
| Pivot Point | 2.87 | 2.87 | 2.84 | 2.86 | 2.87 |
| Support 1 (S1) | 2.70 | 2.76 | 2.64 | 2.68 | 2.51 |
| Support 2 (S2) | 2.57 | 2.68 | 2.56 | 2.48 | |
| Support 3 (S3) | 2.40 | 2.57 | 2.46 | ||
| Support 4 (S4) | 2.38 |
